title: Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ralpha2 as a decoy receptor for IL13.
abstract: Glioma and renal cell carcinoma (RCC) cells express high affinity interleukin 13 (IL13) binding sites, but only RCC cell proliferation was inhibited by IL13. Both of these two cell types are IL2-receptor (gamma)c chain-negative. We thus used these cell models to investigate the patterns of expression of IL13Ralpha1, IL13Ralpha2, and IL4Ralpha chains and the role of IL13Ralpha2 in the response to IL13. Using new specific antibodies and flow cytometry, we observed a similar surface expression of IL4Ralpha and IL13Ralpha1 chains in most RCC and glioma cells, whereas IL13Ralpha2 was only present on five of six glioma cell lines. In all glioma cell lines, the amount of IL13Ralpha2 expression was 10 to 30 times higher than that of the two other chains. Although there was no surface or intracellular expression of IL13Ralpha2, its mRNA was detected in three of seven RCC cell lines. The expression on RCC cells of IL13Ralpha2 mRNA and/or that of high-affinity IL13 binding sites is not sufficient to predict IL13Ralpha2 protein expression. Blocking experiments showed that IL4 and IL13 strongly inhibited RCC cell proliferation through a unique receptor composed of IL4Ralpha and IL13Ralpha1 chains. Using RCC cells stably transfected with IL13Ralpha2 cDNA, we showed that the overexpression of IL13Ralpha2 decreased the response to IL13 but not that to IL4. Our results demonstrate that IL13Ralpha2 acts as a decoy receptor for IL13 and that it may exert a tight regulation of IL13 activity without impairing the IL4 response of the same cell target.
authors.affiliation: INSERM U 131, Institut Paris-Sud sur les Cytokines, Clamart, France.
authors.forename: J
authors.initials: J
authors.lastname: Bernard
authors.forename: D
authors.initials: D
authors.lastname: Treton
authors.forename: C
authors.initials: C
authors.lastname: Vermot-Desroches
authors.forename: C
authors.initials: C
authors.lastname: Boden
authors.forename: P
authors.initials: P
authors.lastname: Horellou
authors.forename: E
authors.initials: E
authors.lastname: Angevin
authors.forename: P
authors.initials: P
authors.lastname: Galanaud
authors.forename: J
authors.initials: J
authors.lastname: Wijdenes
authors.forename: Y
authors.initials: Y
authors.lastname: Richard
mesh_terms: D002292:Carcinoma, Renal Cell / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D016543:Central Nervous System Neoplasms / Q000378:metabolism*; D005910:Glioma / Q000378:metabolism*; D018793:Interleukin-13 / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology; D007680:Kidney Neoplasms / Q000378:metabolism*; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D018123:Receptors, Interleukin / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D053660:Receptors, Interleukin-13; D019948:Receptors, Interleukin-4 / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D014020:Tissue Extracts / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D018793:Interleukin-13; D020033:Protein Isoforms; D012333:RNA, Messenger; D018123:Receptors, Interleukin; D053660:Receptors, Interleukin-13; D019948:Receptors, Interleukin-4; D014020:Tissue Extracts; D015847:Interleukin-4